Table 1.
MEDAG expression in PTMC and its relation.
| Pathological characteristics | Cases | MEDAG expression | P | |
|---|---|---|---|---|
| Low (n = 13) | High (n = 54) | |||
| Age | ||||
| <45 | 33 (49%) | 4 | 29 | 0.138 |
| ≥45 | 34 (51%) | 9 | 25 | |
| Gender | ||||
| Female | 48 (72%) | 9 | 39 | 1 |
| Male | 19 (28%) | 4 | 15 | |
| PTC variants | ||||
| Classcial | 62 (93%) | 13 | 49 | 0.580 |
| Not-classcial | 5 (7%) | 0 | 5 | |
| Extrathyroid invasion | ||||
| No | 61 (91%) | 13 | 48 | 0.609 |
| Yes | 6 (9%) | 2 | 4 | |
| Multicenter tumour | ||||
| No | 46 (69%) | 12 | 34 | 0.049 |
| Yes | 21 (31%) | 1 | 20 | |
| Lymph node metastasis | ||||
| No | 44 (66%) | 13 | 31 | 0.003 |
| Yes | 23 (34%) | 0 | 23 | |
| Distant metastases | ||||
| No | 66 (99%) | 13 | 53 | 1 |
| Yes | 1 (1%) | 0 | 1 | |
| Tumour stage | ||||
| I/II | 61 (91%) | 11 | 50 | 0.329 |
| III/IV | 6 (9%) | 2 | 4 | |
| BRAFv600 mutation | ||||
| No | 4 (6%) | 0 | 4 | 0.579 |
| Yes | 63 (94%) | 13 | 50 | |